Nutritional status predicts adjuvant chemotherapy outcomes for stage III colorectal cancer

Ihara, Kensuke; Yamaguchi, Satoru; Shida, Yohei; Fujita, Junki; Matsudera, Shotaro; Kikuchi, Maiko; Muroi, Hiroto; Nakajima, Masahiro; Sasaki, Kenji; Terauchi, Takashi; Kojima, Kazuyuki

doi:10.23922/jarc.2018-031

Cited by 10 publications

(7 citation statements)

References 20 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous study showed that patients with high OPNI shared a significantly better prognosis than those who had a lower value of OPNI [ 22 ]. Similar results regarding Crohn’s disease and stage III colorectal cancer have also been reported [ 1 , 27 , 28 ]. In our study, the border value of the OPNI was determined to be 42.6 for the TKI-unused group and TKI-unused group according to the survival cut-off analysis in R 3.6.3.…”

Section: Discussionsupporting

confidence: 87%

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors

et al. 2021

View full text Add to dashboard Cite

Background Immunoinflammatory and nutritional markers, such as the peripheral blood neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and Onodera’s prognostic nutritional index (OPNI), have gained considerable attention and have been preliminarily revealed as prognostic markers of gastrointestinal stromal tumors (GISTs). Methods In this study, we first investigated the prognostic value of OPNI in GISTs treated with or without TKIs based on the propensity score matching (PSM) method. All of the patients had received surgical resection for primary GIST, and data from 2010 to 2018 were initially and retrospectively identified from our gastrointestinal center. Recurrence-free survival (RFS) was calculated by the Kaplan–Meier method and compared by the log-rank test. Results The patients were divided into groups treated and not treated with TKIs, and we used the propensity score matching method to homogenize their baseline data. Multivariate Cox proportional hazard regression models were applied to identify associations with outcome variables. A total of 563 GISTs were initially chosen, and 280 of them were included for analysis under the inclusion criteria. After PSM, there were 200 patients included. Multivariate analyses identified OPNI as an independent prognostic marker that was associated with primary site, tumor size, mitotic index, tumor rupture, necrosis, and modified NIH risk classification. Low OPNI (< 42.6; HR 0.409; P < 0.001) was associated with worse RFS. Conclusions Preoperative OPNI is a novel and useful prognostic marker for GISTs both treated and not treated with TKIs. Higher NLR and PLR have negative effects on RFS.

show abstract

Section: Discussionsupporting

confidence: 87%

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The previous studies showed that patients with high OPNI shared a signi cantly better prognosis than those who had a lower value of OPNI [22]. And similar results regarding Crohn's disease and stage III colorectal cancer have been also reported [27,28]. In our study, the border value of the OPNI was determined to be 42.6 for TKIs-used group and TKIs-unused group according to survival cut-off analysis by R 3.6. lymphocytes play an important role in the host immune response, eliminating tumor formation and progression.…”

Section: Discussionsupporting

confidence: 80%

Prognostic Value of Onodera’s Nutritional Index for Intermediate and High Risk Gastrointestinal Stromal Tumors Treated With or Without Tyrosine Kinase Inhibitors

Feng

Tao

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Immunoinflammatory and nutritional markers such as peripheral blood neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and onodera’s prognostic nutritional index (OPNI) have gained considerable attention and revealed preliminaryly as prognostic markers in gastrointestinal stromal tumor (GIST).Methods: In this study, we firstly investigated the prognostic value of OPNI in GIST treated with or without TKIs based on the propensity score matching (PSM) method. All of the patients had received surgical resection for primary GIST, the data from 2010 to 2018 were initially and retrospectively identified from our gastrointestinal center. Recurrence-free survival (RFS) was calculated by the Kaplan-Meier method and compared by the log-rank test.Results: These patients who were treated with TKIs and those who did not were divided into two groups, and we used propensity score matching method to make them have more unified baseline data. Multivariate Cox proportional hazard regression models were applied to identify associations with outcome variables. A total of 563 GISTs were initially chosen and 280 of them were included for analysis under an inclusion criteria. After PSM, there were 200 patients included. Multivariate analyses identified OPNI was an independent prognostic marker, and was associated with primary site, tumor size, mitotic index, tumor rupture, necrosis, and modified NIH risk classification. Low OPNI (<42.6; HR 0.409; P＜0.001) were associated with worse RFS.Conclusions: Preoperative OPNI is a novel and useful prognostic marker for GISTs both treated with or without TKIs. Higher NLR and PLR have negative effects for RFS.

show abstract

Section: Discussionsupporting

confidence: 80%

Prognostic value of Onodera’s Nutritional Index for intermediate and high risk gastrointestinal stromal tumors treated with or without Tyrosine Kinase Inhibitors

Wang¹,

Tao²,

Yu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Immunoinflammatory and nutritional markers such as peripheral blood neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and onodera’s prognostic nutritional index (OPNI) have gained considerable attention and revealed preliminaryly as prognostic markers in gastrointestinal stromal tumor (GIST). Methods In this study, we firstly investigated the prognostic value of OPNI in GIST treated with or without TKIs based on the propensity score matching (PSM) method. All of the patients had received surgical resection for primary GIST, the data from 2010 to 2018 were initially and retrospectively identified from our gastrointestinal center. Recurrence-free survival (RFS) was calculated by the Kaplan-Meier method and compared by the log-rank test. Results These patients who were treated with TKIs and those who did not were divided into two groups, and we used propensity score matching method to make them have more unified baseline data. Multivariate Cox proportional hazard regression models were applied to identify associations with outcome variables. A total of 563 GISTs were initially chosen and 280 of them were included for analysis under an inclusion criteria. After PSM, there were 200 patients included. Multivariate analyses identified OPNI was an independent prognostic marker, and was associated with primary site, tumor size, mitotic index, tumor rupture, necrosis, and modified NIH risk classification. Low OPNI (< 42.6; HR 0.315; P༜0.001) were associated with worse RFS. Conclusions Preoperative OPNI is a novel and useful prognostic marker for GISTs both treated with or without TKIs.

show abstract

Nutritional status predicts adjuvant chemotherapy outcomes for stage III colorectal cancer

Cited by 10 publications

References 20 publications

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors

Prognostic Value of Onodera’s Nutritional Index for Intermediate and High Risk Gastrointestinal Stromal Tumors Treated With or Without Tyrosine Kinase Inhibitors

Prognostic value of Onodera’s Nutritional Index for intermediate and high risk gastrointestinal stromal tumors treated with or without Tyrosine Kinase Inhibitors

Contact Info

Product

Resources

About